Free Trial
→ Why I'm selling my Snapback Indicator for just $7 (From Base Camp Trading) (Ad)tc pixel
NASDAQ:PULM

Pulmatrix Q4 2024 Earnings Results & Report

Pulmatrix logo
$1.31 -0.04 (-2.96%)
Closing price 11/11/2026 04:00 PM Eastern
Extended Trading
$1.34 +0.03 (+2.29%)
As of 11/11/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pulmatrix reported Q4 2024 earnings on March 21, 2025. The company reported EPS of -$0.54.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Pulmatrix EPS Results

Actual EPS
-$0.54
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pulmatrix Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Pulmatrix's Q4 2024 Press ReleasePress Release
(8-K)
Pulmatrix's Q4 2024 Annual reportAnnual report
(10-K)

Pulmatrix Q4 2024 Earnings FAQ

Pulmatrix (NASDAQ:PULM) reported earnings of -$0.54 per share for Q4 2024. The report was announced on Friday, March 21, 2025.

Pulmatrix Earnings Headlines

Eos SENOLYTIX's PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference
November 9 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/09/3398364/0/en/eos-senolytix-s-ptc-2105-reduced-semaglutide-associated-lean-mass-loss-in-aged-mice-data-to-be-presented-at-19th-sarcopenia-cachexia-wasting-disorders-international-conference.html
Pulmatrix (PULM) Projected to Post Quarterly Earnings on Thursday
November 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31177906
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
November 12 at 1:00 AM  |  Behind the Markets (Ad)
Eos SENOLYTIX Reports Preserved Motor Function In Aged Rats With PTC-2105; Stock Down
October 30, 2026  |  rttnews.comhttps://www.rttnews.com/3706597/eos-senolytix-reports-preserved-motor-function-in-aged-rats-with-ptc-2105-stock-down.aspx
Eos SENOLYTIX Reports Interim Data Showing Preserved Physical Function with MitoXcel Geropeptide PTC-2105 in a Second Species, Aged-Rat Study
October 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/30/3392194/0/en/eos-senolytix-reports-interim-data-showing-preserved-physical-function-with-mitoxcel-geropeptide-ptc-2105-in-a-second-species-aged-rat-study.html
Pulmatrix, Inc. stockholders approve merger-related proposals and reverse stock split
October 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/pulmatrix-inc-stockholders-approve-merger-related-proposals-and-reverse-stock-split/ar-AA2gbGBJ
See More Pulmatrix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email.

About Pulmatrix

Pulmatrix (NASDAQ:PULM) is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory and other diseases. The company’s research is based on its iSPERSE dry-powder delivery technology, which is designed to enable efficient administration of pharmaceutical compounds directly to the lungs.

Pulmatrix’s pipeline has included PUR1900, an inhaled formulation of itraconazole being developed for respiratory fungal infections, including allergic bronchopulmonary aspergillosis. The company has also advanced PUR3100, an inhaled formulation of dihydroergotamine intended for the potential acute treatment of migraine. Development programs and indications may change as clinical and regulatory activities progress.

Based in Lexington, Massachusetts, Pulmatrix has historically concentrated on pharmaceutical development rather than commercial product sales. Its operations have primarily involved research, clinical testing and the potential partnering or licensing of inhaled medicines for patients in the United States and other international markets.

View Pulmatrix Profile
Earnings Tools